Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNBELIEVABLE: 3 | History Defined

Retatrutide Will Not Reach the FDA Until Early 2027, Leaving No Price and No Coverage Decision to Point To

Lilly will not file retatrutide with the FDA until early 2027. What that delay means for cost, insurance coverage, and patients considering waiting.

Medical Daily

Eli Lilly Stock: Analyst Estimates & Ratings

Eli Lilly's market-beating performance has done little to temper Wall Street's optimism, with analysts continuing to see meaningful upside in the stock.

Barchart

Bank of America CEO Says The Company Spends $250 Million A Year on GLP-1 Drugs for Their Employees. He Calls It a Good Investment

Bank of America CEO Brian Moynihan said the company has dramatically increased its investment in medications such as Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Zepbound.

International Business Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Lost Weight but Gained It Back? Scientists Say Your Brain May Be Secretly Working Against You

New research suggests the brain may "remember" your highest weight and fight to regain it after weight loss, shedding light on why dieting often fails and how drugs like Wegovy and Mounjaro may help.

Medical Daily

Eli Lilly's Weight-Loss Empire Keeps Expanding As Mounjaro, Zepbound Generate Nearly $15 Billion

Eli Lilly and Co. (NYSE:LLY) stock traded higher Wednesday after the drugmaker reported second-quarter results that topped Wall Street expectations and raised its full-year revenue outlook, driven by continued demand for its diabetes and obesity treatments.

Benzinga

Opposite Actions on the Same Brain Receptor Both Reduced Food Intake in Mice, Cambridge Team Reports

Cambridge researchers found that activating a receptor in the brainstem and blocking it in the hypothalamus both cut food intake in mice.

Medical Daily

Eli Lilly Raises Sales Forecast As Weight Loss Drug Demand Soars. Its Stock is Climbing

Eli Lilly posted stronger-than-expected second-quarter earnings and revenue, boosted by surging demand for Zepbound and Mounjaro, while its newly launched obesity pill Foundayo made its first contribution to quarterly sales.

International Business Times

Read news from The Economist, FT, and more,
with one subscription

Mouse Study Adds Evidence That Persistent Hunger, Not Willpower, Drives Weight Regain

A mouse study found lasting hyperphagia after weight loss, adding to evidence that the body defends a higher weight. Here is what it does and does not show.

Medical Daily

Three Daily Servings of Full-Fat Dairy Did Not Worsen Cholesterol or Body Composition in a 12-Week Trial

A 12-week randomized trial of 74 adults found that three daily servings of full-fat dairy did not worsen blood lipids or body composition.

Medical Daily

Mounjaro sales double this year as obesity drug boom prevails, says maker

The manufacturer said its obesity medications Mounjaro and Zepbound were driving an acceleration of its overall sales.

Evening Standard

Sales in weight-loss drug Mounjaro double amid surging market appetite

Eli Lilly’s chief executive David Ricks told investors that it was ‘building for the future’

The Independent UK

Novo CEO says setbacks demand faster research, acquisitions as investors fret over pipeline

Novo Nordisk CEO Mike Doustdar said the company will speed up research and pursue smaller acquisitions to strengthen its drug pipeline after recent trial setbacks. The company raised its 2026 sales and profit outlook, but shares fell as investors focused on weaker-than-expected Wegovy pill sales and another setback for obesity…

The Economic Times

Novo Nordisk Stock Slides After Outlook Disappoints. But Wegovy Sales Continue to Climb

U.S.-listed shares of Novo Nordisk fell more than 6% after the company raised its full-year 2026 outlook but signaled that sales and profit could still decline compared with the previous year.

International Business Times

A Next-Generation Obesity Drug Has Been Released By Eli Lilly in Early Access to Select Patients

Eli Lilly will offer early access to the investigational obesity drug retatrutide after positive Phase 3 trials showed significant weight-loss results.

Medical Daily

Get all your
news in one place.

100's of premium titles.
One news app.

The Economic Times

Drugmaker Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts

Pfizer has reported impressive second-quarter earnings, driven by the success of Eliquis and newly acquired pharmaceutical products. The company is planning $2.5 billion in cost-saving measures expected to be in place by 2029. With a focus on innovative treatments, Pfizer aims to reduce reliance on older, high-grossing medications and looks…

Medical Daily

Analysis of 19 Trials Finds GLP-1 Results Differ by Drug and Dose, Pointing Toward More Tailored Obesity Care

A 19-trial analysis found GLP-1 drugs and doses differ across seven heart and metabolic measures. It does not yet tell doctors which one to pick.

Medical Daily

New Study Links Daily Avocado to Lower Heart Disease Risk and Here's What It Means for Your Heart

A new study suggests eating one avocado daily may improve cholesterol markers linked to heart disease when included in an overall heart-healthy diet.

Marie Claire

What Is Retatrutide? The Next-Gen GLP-1 Poised to Become the Most In-Demand Peptide

A deep dive into Retatrutide shows promise—and a lot of danger.

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Ultra-processed food companies hindering health drives by suing countries, says WHO

Exclusive: Director general accuses corporations of obstructing efforts to tackle obesity crisis after investigation by Guardian and others

The Conversation

Alcohol’s hidden calories: product labels could help fight obesity in South Africa

South Africa is grappling with an obesity crisis. Nearly half of adults are overweight or obese. Public discussion often focuses on ultra-processed foods and sugary drinks as reasons for weight gain. But there’s another source of calories that’s often overlooked: alcoholic drinks.

Medical Daily

GLP-1 Drugs Did Not Lower Relapse Risk in Crohn's and Colitis Patients, a Large Claims Analysis Found

A claims study found GLP-1 drugs did not reduce IBD relapse in patients with obesity or diabetes, and did not raise safety events.

Kiplinger

GLP-1 Medicare Coverage: How to Get It for $50 (And the Catch)

A new CMS program finally brings Wegovy and Zepbound within reach for seniors. But a hidden rule about your deductible could cost you thousands.

Medical Daily

Denied Coverage For Wegovy Or Zepbound? Here Is What The Latest Value Assessment Says About Price And Access

Denied for Wegovy or Zepbound? A new value analysis explains why plans refuse coverage and what exceptions and appeals actually involve.

Medical Daily

ICER Finds Weight-Loss Drugs Cost-Effective, But Analysts Warn the Projected Savings Depend on Patients Staying On Them

ICER finds GLP-1s cost-effective for obesity, but analysts warn projected savings assume patients stay on treatment. What it means for coverage.

The Guardian - AU

Millions of people are losing weight using GLP-1s. How do the drugs affect their love lives?

Prescribing doctors often warn of the medications’ potential side-effects – but unexpected impacts on romantic relationships are less understood

1 2 3 4 5

People

Tedros Adhanom Ghebreyesus

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.